Merck seeks to develop novel T-cell engager therapies with TriTAC platform: GlobalData
The deal includes the novel HPN-217 and HPN-328 compounds, which are currently undergoing Phase II clinical trials for various…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
tarlatamab
First-in-class DLL3-targeting BiTE could be the next big player in SCLC treatment: GlobalData
The drug is forecast to achieve peak sales of $788 million by 2029